<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870764</url>
  </required_header>
  <id_info>
    <org_study_id>TaizhouFPH-001</org_study_id>
    <nct_id>NCT02870764</nct_id>
  </id_info>
  <brief_title>The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris</brief_title>
  <acronym>DOLPHIN</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Fourth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taizhou Fourth People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, adaptive clinical trial, which will
      assess the effect of DanshenDuofensuanyan[Danshen (a kind of Chinese herbal drug) extract]
      treatment on Lipoprotein associated phospholipase A2 level in patients with stable angina
      pectoris.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum level of Lp-PLA2</measure>
    <time_frame>up to Day 60 after discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in each treatment group who had clinically significant change as defined by the angina-frequency score on the Seattle Angina Questionnaire</measure>
    <time_frame>Day 0 and Day 60 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid arterial intima-media wall thickness</measure>
    <time_frame>Day0 and Day 60 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Canadian Cardiovascular Society (CCS) grading of angina pectoris</measure>
    <time_frame>Day 0 and Day 60 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the electrocardiogram (EKG)</measure>
    <time_frame>Day 0 and Day 60 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Serum Lipid, the high-sensitivity C-Reactive Protein(hs-CRP) and the Platelet Aggregation Rate</measure>
    <time_frame>Day 0 and Day 60 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new-onset major vascular events</measure>
    <time_frame>up to 60 days after discharge</time_frame>
    <description>Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe hemorrhages</measure>
    <time_frame>up to 60 days after discharge</time_frame>
    <description>The definition of &quot;Severe hemorrhages&quot; is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate hemorrhages</measure>
    <time_frame>up to 60 days after discharge</time_frame>
    <description>The definition of &quot;moderate hemorrhages&quot; is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Angina, Stable</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Dan-shen extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dan-shen extract</intervention_name>
    <description>A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza</description>
    <arm_group_label>Dan-shen extract</arm_group_label>
    <other_name>salvianolic acid</other_name>
    <other_name>Depside salt from Salvia Miltiorrhiza</other_name>
    <other_name>Danshen Dropping Pill</other_name>
    <other_name>dropping salvia pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard medical care</intervention_name>
    <description>Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).</description>
    <arm_group_label>Dan-shen extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 years-75 years;

          2. Written informed consent;

          3. Patients with a clinical diagnosis of chronic stable angina, which fulfil one of the
             following conditions:

               1. Symptoms that support the diagnosis of chronic angina and/or a history of an
                  abnormal exercise response limited by angina and/or electrocardiograph (ECG)
                  changes

               2. a history of myocardial infarction and ST-T changes,

               3. stenosis of more than 50 % in at least one major epicardial coronary artery, as
                  shown by coronary angiography or computed tomography angiography,

               4. Coronary heart disease confirmed by radionuclide angiocardiography;

          4. Patients with moderate angina pectoris, which is defined as Grade II or III on the
             Canadian Cardiovascular Society Angina Grading Scale.

        Exclusion Criteria:

          1. Patients with severe complications that would complicate the condition, as assessed by
             the investigator, including liver or renal dysfunction, severe cardiopulmonary
             dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, a history
             of epilepsy or cerebral haemorrhage.

          2. Patients who were angina-free during the run-in period without taking any drug.

          3. Patients who experienced myocardial infarction or who were classified as Grade IV on
             the Canadian Cardiovascular Society Angina Grading Scale within the preceding 3
             months.

          4. Patients with chest pain that is caused by any other disease (e.g., acute myocardial
             infarction, severe neurosis, menopausal syndrome or hyperthyroidism).

          5. Patients with a history of drug-induced bleeding or a history of bleeding caused by
             warfarin.

          6. Patients with a history of haematopoietic disorder.

          7. Patients who have had surgery within the previous 4 weeks or who have a haemorrhagic
             tendency.

          8. Women who are pregnant or lactating or who have a positive pregnancy test, or women
             who have a menstrual period at baseline.

          9. Patients who are participating in other trials or who have participated in other
             trials within the past 3 months.

         10. Patients with a history of allergy or with a known or suspected allergy to the study
             drug.

         11. Patients with a known or suspected history of alcohol or drug abuse within the past 2
             years.

         12. Patients with a mental disorder.

         13. Family members or relatives of the study centre staff.

         14. Inability to adhere to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A'Di Chen, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Taizhou Fourth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunling Wang, Bachelor</last_name>
    <phone>008613921709559</phone>
    <email>59201291@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taizhou Fourth People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Jiangsu</state>
        <zip>225300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bailing Su, MD</last_name>
      <phone>0086052380185012</phone>
      <email>tzsybgs055@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Haoshen Wang, MD</last_name>
      <phone>008613952613616</phone>
      <email>billet1116@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li B, Wang Y, Lu J, Liu J, Yuan Y, Yu Y, Wang P, Zhao X, Wang Z. Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials. 2015 Dec 9;16:561. doi: 10.1186/s13063-015-1076-4.</citation>
    <PMID>26654631</PMID>
  </reference>
  <reference>
    <citation>Wang PQ, Li DD, Dong W, Liu J, Yu YN, Shen CT, Chen QG, Chen BW, Chen YD, Wang Z. Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials. 2015 Oct 21;16:474. doi: 10.1186/s13063-015-0998-1.</citation>
    <PMID>26489511</PMID>
  </reference>
  <reference>
    <citation>Yao Y, Feng Y, Lin W. Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris. Int J Cardiol. 2015 Mar 1;182:46-7. doi: 10.1016/j.ijcard.2014.12.112. Epub 2014 Dec 29.</citation>
    <PMID>25585358</PMID>
  </reference>
  <reference>
    <citation>Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol. 2007 Sep 14;121(1):9-22. Epub 2007 Mar 23. Review.</citation>
    <PMID>17363091</PMID>
  </reference>
  <reference>
    <citation>Cai A, Li G, Chen J, Li X, Li L, Zhou Y. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc Disord. 2015 Feb 26;15:14. doi: 10.1186/s12872-015-0001-9.</citation>
    <PMID>25879827</PMID>
  </reference>
  <reference>
    <citation>White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.</citation>
    <PMID>24152981</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>September 11, 2016</last_update_submitted>
  <last_update_submitted_qc>September 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taizhou Fourth People's Hospital</investigator_affiliation>
    <investigator_full_name>ChunLing Wang</investigator_full_name>
    <investigator_title>Attending Doctor</investigator_title>
  </responsible_party>
  <keyword>Danshenduofensuanyan</keyword>
  <keyword>Lp-PLA2</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>Salvia miltiorrhiza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We could provide individual participant data without leaking the patients' personal information if needed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

